Associated Genetic Biomarkers
PARP1 Loss is present in 0.08% of AACR GENIE cases, with chronic lymphocytic leukemia/small lymphocytic lymphoma, prostate adenocarcinoma, conventional glioblastoma multiforme, glioblastoma, and cutaneous melanoma having the greatest prevalence .
PARP1 Loss serves as an inclusion eligibility criterion in 5 clinical trials, of which 5 are open and 0 are closed. Of the trials that contain PARP1 Loss as an inclusion criterion, 1 is phase 1 (1 open) and 4 are phase 2 (4 open).
Trials with PARP1 Loss in the inclusion eligibility criteria most commonly target malignant solid tumor, breast carcinoma, and melanoma .
Adavosertib, atezolizumab, capecitabine, carboplatin, and copanlisib are the most frequent therapies in trials with PARP1 Loss as an inclusion criteria .
Significance of PARP1 Loss in Diseases
Malignant Solid Tumor +
PARP1 is altered in 1.47% of malignant solid tumor patients with PARP1 Loss present in 0.03% of all malignant solid tumor patients .
PARP1 Loss is an inclusion criterion in 3 clinical trials for malignant solid tumor, of which 3 are open and 0 are closed. Of the trials that contain PARP1 Loss and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) .
PARP1 is altered in 3.03% of melanoma patients with PARP1 Loss present in 0.09% of all melanoma patients .
PARP1 Loss is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains PARP1 Loss and melanoma as inclusion criteria, 1 is phase 2 (1 open) .
Breast Carcinoma +
PARP1 is altered in 1.88% of breast carcinoma patients with PARP1 Loss present in 0.02% of all breast carcinoma patients .
PARP1 Loss is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP1 Loss and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.